이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Bavarian Nordic 미래 성장

Future 기준 확인 1/6

Bavarian Nordic 의 수익은 연간 2% 감소할 것으로 예상되는 반면, 연간 수익은 5.7% 로 증가할 것으로 예상됩니다. 5.7% 연간. EPS는 연간 0.8% 만큼 쇠퇴할 것으로 예상됩니다. 자기자본이익률은 3년 후 7.8% 로 예상됩니다.

주요 정보

5.7%

수익 성장률

-0.8%

EPS 성장률

Biotechs 수익 성장	30.9%
매출 성장률	-2.0%
향후 자기자본 수익률	7.8%
애널리스트 커버리지	Low
마지막 업데이트	28 Jun 2024

최근 미래 성장 업데이트

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

May 12

Recent updates

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

May 12

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 09

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Feb 26

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Jan 03

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Dec 10

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Nov 15

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Aug 17

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Apr 19

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Jan 03

Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?

Sep 15

Rainbows and Unicorns: Bavarian Nordic A/S (CPH:BAVA) Analysts Just Became A Lot More Optimistic

Jul 24

Industry Analysts Just Made A Notable Upgrade To Their Bavarian Nordic A/S (CPH:BAVA) Revenue Forecasts

Jun 14

Analyst Forecasts Just Became More Bearish On Bavarian Nordic A/S (CPH:BAVA)

May 31

Is Bavarian Nordic (CPH:BAVA) Using Debt In A Risky Way?

May 06

Bavarian Nordic A/S (CPH:BAVA) Analysts Just Cut Their EPS Forecasts Substantially

Mar 13

수익 및 매출 성장 예측

CPSE:BAVA - 애널리스트의 미래 추정치 및 과거 재무 데이터 (DKK Millions )
날짜	수익	수익	잉여 현금 흐름	작전 현금	평균 애널리스트 수
12/31/2026	5,202	923	1,737	1,768	3
12/31/2025	5,084	935	1,680	1,831	5
12/31/2024	5,254	778	-38	263	4
3/31/2024	6,642	984	1,028	1,769	N/A
12/31/2023	7,062	1,475	142	1,119	N/A
9/30/2023	5,906	723	-793	751	N/A
6/30/2023	5,533	1,076	-979	568	N/A
3/31/2023	4,083	301	-1,344	-18	N/A
12/31/2022	3,151	-347	-1,162	220	N/A
9/30/2022	2,404	-599	-1,345	-109	N/A
6/30/2022	1,849	-693	-1,342	-101	N/A
3/31/2022	1,683	-606	-1,477	-215	N/A
12/31/2021	1,898	-465	-1,417	-358	N/A
9/30/2021	1,583	-737	-1,541	-663	N/A
6/30/2021	1,693	-629	-1,279	-478	N/A
3/31/2021	2,022	-368	-727	20	N/A
12/31/2020	1,852	278	-135	572	N/A
9/30/2020	1,914	606	-1,613	981	N/A
6/30/2020	1,499	481	-1,970	623	N/A
3/31/2020	901	267	-2,427	227	N/A
12/31/2019	662	-347	-2,947	-276	N/A
9/30/2019	554	-402	-645	-262	N/A
6/30/2019	631	-271	-529	-204	N/A
3/31/2019	616	-279	-408	-152	N/A
12/31/2018	501	-362	-500	-289	N/A
9/30/2018	360	-445	-647	-467	N/A
6/30/2018	873	-151	-706	-564	N/A
3/31/2018	1,184	5	-258	-158	N/A
12/31/2017	1,370	181	N/A	216	N/A
9/30/2017	1,745	453	N/A	1,030	N/A
6/30/2017	1,463	225	N/A	880	N/A
3/31/2017	1,182	153	N/A	501	N/A
12/31/2016	1,007	31	N/A	268	N/A
9/30/2016	909	-54	N/A	-539	N/A
6/30/2016	536	-202	N/A	-345	N/A
3/31/2016	808	-115	N/A	-561	N/A
12/31/2015	1,021	59	N/A	105	N/A
9/30/2015	1,244	155	N/A	818	N/A
6/30/2015	1,390	186	N/A	815	N/A
3/31/2015	1,166	70	N/A	1,018	N/A
12/31/2014	1,217	26	N/A	339	N/A
9/30/2014	1,013	-99	N/A	-63	N/A
6/30/2014	1,107	-61	N/A	-105	N/A
3/31/2014	1,293	-12	N/A	180	N/A
12/31/2013	1,213	-47	N/A	147	N/A
9/30/2013	1,142	-82	N/A	32	N/A

애널리스트 미래 성장 예측

수입 대 저축률: BAVA 의 연간 예상 수익 증가율( 5.7% )이 saving rate( 0.9% 보다 높습니다. ).

수익 vs 시장: BAVA 의 연간 수익( 5.7% ) Danish 시장( 13% 보다 느리게 성장할 것으로 예상됩니다. 13% 연간).

고성장 수익: BAVA 의 수입은 증가할 것으로 예상되지만 상당히 증가하지는 않을 것입니다.

수익 대 시장: BAVA 의 수익은 향후 3년간 감소할 것으로 예상됩니다(연간 -2% ).

고성장 수익: BAVA 의 수익은 향후 3년 동안 감소할 것으로 예상됩니다(연간 -2% ).

주당 순이익 성장 예측

미래 자기자본 수익률

미래 ROE: BAVA 의 자본 수익률은 3년 내에 최저 수준이 될 것으로 예상됩니다( 7.8 %).

Bavarian Nordic 미래 성장

Future 기준 확인 1/6

주요 정보

최근 미래 성장 업데이트

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Price target increased by 9.4% to kr.293

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Consensus EPS estimates increase by 40%

Recent updates

Bavarian Nordic A/S Submits Marketing Authorization Application for Its Chikungunya Vaccine Candidate to Ema

Investor sentiment improves as stock rises 18%

Laurence De Moerlooze to Leave Bavarian Nordic A/S as Executive Vice President and Chief Medical Officer

Results: Bavarian Nordic A/S Delivered A Surprise Loss And Now Analysts Have New Forecasts

First quarter 2024 earnings released: kr.1.50 loss per share (vs kr.5.10 profit in 1Q 2023)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2024

Bavarian Nordic A/S Initiates Rolling Submission of Biologics License Application with FDA for Chikungunya Vaccine Candidate

Deputy Chairman exercised options to buy kr.123k worth of stock.

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Bavarian Nordic A/S Receives Approval of Smallpox and Mpox Vaccine in Switzerland

CEO & President exercised options to buy kr.1.4m worth of stock.

Full year 2023 earnings released: EPS: kr.19.20 (vs kr.4.93 loss in FY 2022)

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2024

Price target increased by 9.4% to kr.293

Bavarian Nordic A/S' (CPH:BAVA) Business And Shares Still Trailing The Industry

Bavarian Nordic A/S (CPH:BAVA) Shares Could Be 45% Below Their Intrinsic Value Estimate

Third quarter 2023 earnings released: kr.4.40 loss per share (vs kr.0.20 profit in 3Q 2022)

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Here's Why Bavarian Nordic (CPH:BAVA) Can Manage Its Debt Responsibly

Bavarian Nordic A/S's Mpox Vaccine Receives Recommendation from U.S. CDC Advisory Committee for Routine Use in Adults at Risk

Investor sentiment improves as stock rises 15%

Bavarian Nordic A/S Reports Additional Phase 3 Results and Provides Update on Development Program for its cVLP-Based COVID-19 Booster Vaccine Candidate, ABNCoV2

Bavarian Nordic A/S, Annual General Meeting, Apr 16, 2024

Does Bavarian Nordic (CPH:BAVA) Have A Healthy Balance Sheet?

New major risk - Revenue and earnings growth

New minor risk - Share price stability

Bavarian Nordic A/S Provides Update on RSV Vaccine Program

Investor sentiment deteriorates as stock falls 26%

Bavarian Nordic A/S Reports Data from A Phase 3 Clinical Trial of Its Vlp-Based Chikungunya Virus Vaccine in Adults >=65 Years of Age Study Successfully Met Its Primary Endpoints

Bavarian Nordic A/S Reports 12-Month Durability Data from Phase 2 Clinical Trial of Covid-19 Vaccine Candidate

Consensus EPS estimates increase by 40%

Bavarian Nordic A/S acquired Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $384 million.

Bavarian Nordic A/S Provides Earnings Guidance for the Year 2023

Improved Revenues Required Before Bavarian Nordic A/S (CPH:BAVA) Shares Find Their Feet

Full year 2022 earnings released: kr.4.90 loss per share (vs kr.7.37 loss in FY 2021)

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S entered into an agreement to acquire Travel health business of Emergent International Inc. and Emergent Travel Health Inc. for $380 million.

Bavarian Nordic A/S Provides Earnings Guidance for Fiscal Year 2023

Bavarian Nordic A/S Provides Revenue Guidance for Fiscal Year 2022

Is Bavarian Nordic (CPH:BAVA) Weighed On By Its Debt Load?

Bavarian Nordic Completes Enrollment in Global Phase 3 Trial of RSV Vaccine Candidate for Older Adults

Chairman recently sold kr.508k worth of stock

Less than half of directors are independent

Third quarter 2022 earnings released: EPS: kr.0.20 (vs kr.1.30 loss in 3Q 2021)

Bavarian Nordic A/S Maintains Earnings Guidance for the Year 2022

Bavarian Nordic A/S Announces Covid-19 Booster Vaccine Candidate Demonstrates Durable Antibody Response Six Months After Vaccination in Phase 2 Clinical Trial

Bavarian Nordic A/S Appoints Luc Debruyne as Board of Directors

Bavarian Nordic (CPH:BAVA) Has Debt But No Earnings; Should You Worry?

Bavarian Nordic A/S Revises Earnings Guidance for the Full Year 2022

Bavarian Nordic Announces Initiation of a Global Phase 3 Clinical Trial of its COVID-19 Booster Vaccine Candidate

Bavarian Nordic A/S, Annual General Meeting, Mar 30, 2023

Bavarian Nordic A/S to Report Fiscal Year 2022 Final Results on Mar 02, 2023

Second quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Price target increased to kr.418

Bavarian Nordic A/S Provides Revenue Guidance for the Year 2022

Consensus forecasts updated

Bavarian Nordic A/S Receives U.S. and Eu Approvals of Its Fill and Finish Vaccine Manufacturing Facility

Price target increased to kr.390

Rainbows and Unicorns: Bavarian Nordic A/S (CPH:BAVA) Analysts Just Became A Lot More Optimistic

Bavarian Nordic A/S Receives Positive CHMP Opinion on the Extension of Vaccine Label to Include Monkeypox

Consensus estimates of losses per share improve by 21%

Bavarian Nordic A/S Raises Earnings Guidance for the Financial Guidance for 2022

Bavarian Nordic A/S Provides an Update on the Phase 3 Development of ABNCoV2, A VLP-Based, Non-Adjuvanted Covid-19 Booster Vaccine Candidate

Bavarian Nordic A/S Revises Revenue Guidance for the Year 2022

Industry Analysts Just Made A Notable Upgrade To Their Bavarian Nordic A/S (CPH:BAVA) Revenue Forecasts

Consensus revenue estimates increase by 13%

Consensus forecasts updated

Bavarian Nordic A/S Raises Financial Guidance for the Year 2022